Survival studies performed in the B16 melanoma and CT26 colon carcinoma tumor models showed that the combination of PD-1 blockade with GM-CSF-secreting tumor cell immunotherapy leads to improved antitumor responses by augmenting the tumor-reactive T-cell responses induced by the cellular immunotherapy (59). This evidence concerns the gene PDCD1 and melanoma.